| |
| |
|
| Insider
Information: |
Countouriotis Athena |
| Relationship: |
Director |
| City: |
San Diego |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
210,157 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$3,967,861 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
210,157 |
|
|
| Total
Value |
$3,967,861 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
3
|
1
|
|
Stock
price went up :
|
2
|
0
|
| Stock
price went down : |
1
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
2.0
|
-1.0
|
| Percentage
Gain/Loss : |
 66.8%
|
 -100.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Halozyme Therapeutics Inc |
HALO |
SVP and Chief Medical ... |
2017-02-03 |
39,077 |
2015-12-31 |
0 |
Premium* |
|
|
Adverum Biotechnologies, Inc |
AAVL |
SVP, Chief Medical Off... |
2017-06-19 |
150,000 |
2017-06-19 |
0 |
Premium* |
|
|
Turning Point Therapeutics, Inc. |
TPTX |
President & CEO, Direc... |
2022-08-17 |
0 |
2019-09-10 |
0 |
Premium* |
|
|
Passage Bio, Inc. |
PASG |
Director |
2020-03-24 |
18,900 |
2020-03-03 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
Director |
2023-12-27 |
2,180 |
2023-12-27 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| BMRN |
Biomarin Pharmaceutical I... |
Director |
– • – |
2023-12-27 |
4 |
A |
$0.00 |
$0 |
D/D |
2,180 |
2,180 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
President & CEO |
• • – |
2022-08-17 |
4 |
D |
$76.00 |
$8,432,884 |
D/D |
(110,959) |
0 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
President & CEO |
• • – |
2022-02-09 |
4 |
A |
$0.00 |
$0 |
D/D |
62,400 |
110,330 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
President & CEO |
• • – |
2022-02-09 |
4 |
S |
$36.30 |
$107,847 |
D/D |
(2,971) |
47,930 |
0 |
% |
|
| TPTX |
Turning Point Therapeutic... |
President & CEO |
• • – |
2021-02-11 |
4 |
AS |
$136.45 |
$1,228,446 |
D/D |
(8,942) |
50,195 |
0 |
% |
|
| TPTX |
Turning Point Therapeutic... |
President & CEO |
• • – |
2021-02-11 |
4 |
OE |
$3.20 |
$28,614 |
D/D |
8,942 |
59,137 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
President & CEO |
• • – |
2021-02-10 |
4 |
OE |
$3.20 |
$81,254 |
D/D |
25,392 |
75,587 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
President & CEO |
• • – |
2021-02-10 |
4 |
AS |
$134.34 |
$3,461,116 |
D/D |
(25,392) |
50,195 |
0 |
% |
|
| TPTX |
Turning Point Therapeutic... |
President & CEO |
• • – |
2021-02-09 |
4 |
AS |
$136.29 |
$3,559,475 |
D/D |
(25,666) |
50,195 |
0 |
% |
|
| TPTX |
Turning Point Therapeutic... |
President & CEO |
• • – |
2021-02-09 |
4 |
OE |
$3.20 |
$82,131 |
D/D |
25,666 |
75,861 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
President & CEO |
• • – |
2021-02-08 |
4 |
A |
$0.00 |
$0 |
D/D |
22,617 |
50,195 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
President & CEO |
• • – |
2020-05-21 |
4 |
B |
$60.00 |
$249,960 |
D/D |
4,166 |
26,872 |
2.81 |
% |
|
| PASG |
Passage Bio, Inc. |
Director |
– • – |
2020-03-24 |
4 |
B |
$14.98 |
$149,750 |
D/D |
10,000 |
18,900 |
2.39 |
% |
|
| PASG |
Passage Bio, Inc. |
Director |
– • – |
2020-03-03 |
4 |
B |
$18.00 |
$160,200 |
D/D |
8,900 |
8,900 |
2.39 |
% |
|
| TPTX |
Turning Point Therapeutic... |
President & CEO |
• • – |
2019-12-10 |
4 |
A |
$31.13 |
$21,976 |
D/D |
706 |
22,706 |
0 |
- |
|
| TPTX |
Turning Point Therapeutic... |
President & CEO |
• • – |
2019-09-10 |
4 |
B |
$45.00 |
$450,000 |
D/D |
10,000 |
22,000 |
2.81 |
- |
|
| AAVL |
Adverum Biotechnologies, ... |
SVP, Chief Medical Officer |
• – – |
2017-06-19 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
150,000 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP and Chief Medical Officer |
• – – |
2017-02-03 |
4 |
D |
$12.26 |
$84,594 |
D/D |
(6,900) |
39,077 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP and Chief Medical Officer |
• – – |
2017-02-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,496 |
45,977 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP and Chief Medical Officer |
• – – |
2017-01-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
27,481 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP and Chief Medical Officer |
• – – |
2016-06-30 |
4 |
D |
$8.63 |
$923 |
D/D |
(107) |
19,981 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP and Chief Medical Officer |
• – – |
2016-06-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,450 |
20,088 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP and Chief Medical Officer |
• – – |
2016-01-05 |
4 |
D |
$16.39 |
$53,382 |
D/D |
(3,257) |
13,638 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP and Chief Medical Officer |
• – – |
2016-01-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
16,895 |
0 |
- |
|
| HALO |
Halozyme Therapeutics Inc |
SVP and Chief Medical Officer |
• – – |
2015-12-31 |
4 |
D |
$17.33 |
$98,001 |
D/D |
(5,655) |
9,395 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
